Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2026-03-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
拓新药业集团股份有限公司2025年12月31日内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It references auditing standards and responsibilities related to internal control over financial reporting as of December 31, 2025. The content includes an auditor's opinion on the effectiveness of internal controls, typical of a standalone audit report rather than a full annual report. The document length is 812 characters, which is short but contains substantive audit opinion content, not merely an announcement. Therefore, it fits the category of an Audit Report / Information (AR). FY 2025
2026-03-27 Chinese
2025年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2025 by 拓新药业集团股份有限公司. It discusses the company's internal control evaluation, including control environment, risk assessment, control activities, and supervision. It contains detailed descriptions of internal control structures, risk management, and evaluation standards. The document is lengthy (over 13,000 characters) and contains substantive content about internal controls rather than just an announcement or summary. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an audit report (AR) or earnings release (ER). It is a specialized report focused on internal control evaluation, which aligns with the category of Audit Report / Information (AR), as it includes results of internal control assessments and compliance with regulatory internal control standards. Therefore, the most appropriate classification is AR (Audit Report / Information). FY 2025
2026-03-27 Chinese
第五届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 10th meeting of the 5th Board of Directors of the company 拓新药业集团股份有限公司. It includes approvals of the 2025 Annual Report and its summary, the 2025 President's Work Report, the 2025 Board Work Report, the 2025 Financial Final Report, profit distribution plans, remuneration plans, internal control self-evaluation report, and multiple proposals related to a simplified procedure for issuing shares to specific investors. It also includes appointments and resignations of senior management and directors, and the scheduling of the 2025 Annual General Meeting. The document is a formal board meeting resolution announcement, not the actual annual report or financial statements themselves. It references that the full reports are disclosed elsewhere (on the cninfo website). The document also contains management and board decisions on capital raising via share issuance. Given the content, the document is primarily a Board/Management Information announcement about board meeting resolutions, including management and board reports and capital raising plans. It is not a full Annual Report (10-K), nor a simple Capital/Financing Update (CAP) because it covers broader board resolutions including management changes and report approvals. It is not a Regulatory Filing (RNS) because it is a formal board meeting resolution announcement. Therefore, the best fitting category is Board/Management Information (MANG). Confidence is high due to the detailed nature and the focus on board meeting resolutions and management appointments.
2026-03-27 Chinese
会计师事务所关于前次募集资金使用情况的鉴证报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use of previously raised funds by 拓新药业集团股份有限公司, including verification by an accounting firm, detailed descriptions of fund amounts, usage, changes in investment projects, and investment benefits. It references compliance with regulations from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes attachments with detailed tables on fund usage and project benefits. The document is over 11,000 characters, indicating it is a full report rather than a brief announcement. The content focuses on the use of capital raised in a prior fundraising event, which aligns with a capital/financing update report rather than a general annual report or audit report. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2026-03-27 Chinese
拓新药业集团股份有限公司2026年度以简易程序向特定对象发行股票募集资金使用的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2026年度以简易程序向特定对象发行股票募集资金使用的可行性分析报告," which translates to "2026 Feasibility Analysis Report on the Use of Funds Raised by a Simplified Procedure Private Placement." The content details the planned use of funds raised from a specific stock issuance, including investment projects, feasibility analysis, impact on company operations, financial status, and other related information. It is focused on capital raising and the use of proceeds from a financing activity. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. The document is not a simple announcement of a report publication but a substantive report on the capital raising and fund usage plan. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2026-03-27 Chinese
独立董事2025年度述职报告（靳焱顺-已离任）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2025 Annual Work Report" for the company. It details the independent director's attendance at board and shareholder meetings, participation in committees, and fulfillment of duties during the year 2025. The content focuses on the director's report on their activities and responsibilities rather than financial data or audit results. It is a formal report by a board member about their work and governance role, which fits the category of Board/Management Information (MANG). The document length is relatively short (2228 characters), and it is not an announcement or a certification but a substantive report on board member activities. Therefore, the appropriate classification is MANG with high confidence.
2026-03-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.